再生元製藥公司 REGN 深 滬
等待開盤 02-04 09:30:00 美东时间
763.41
+8.390
+1.11%
華盛通- 最 高773.715
- 今 開745.53
- 成交量 38.14万股
- 最 低 742.7371
- 昨 收 755.02
- 總市值 824.48亿
- 52周最高 821.11
- 市盈率 靜 18.40
- 換手率 0.35%
- 52周最低 474.7269
- 委 比 96.99%
- 總股本 1.08亿
- 歷史最高 1207.6799
- 量 比 0.55
- 振 幅 4.10%
- 歷史最低 39.31
- 每 手 1
- 風險率 83.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股机会日报 | 贵金属“大逆转”！金银价再度大涨，机构建议市场回稳再进场；闪迪盘前续涨4%，年内已累涨180%
贵金属“大逆转”！金银价再度大涨，机构建议市场回稳后再进场；存储缺货潮或持续至28年！闪迪盘前续涨4%，年内已累涨180%；受SpaceX与xAI合并催化，太空概念股盘前反弹>>
今天 21:15
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
赛诺菲遗传性疾病药物后期临床试验结果喜忧参半
法国制药企业赛诺菲 2 月 2 日宣布，其一款试验性遗传性疾病治疗药物，在针对特定类型戈谢病患者的后期临床试验中展现出治疗潜力，但在另一项针对法布里病的临床...
02-02 17:09
U.S. RESEARCH ROUNDUP-Air Products, Chevron, UnitedHealth
U.S. RESEARCH ROUNDUP-Air Products, Chevron, UnitedHealth Feb 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Definium Air Products, Chevron and UnitedHealth on Monday. HIGHLIGHTS * Air Products APD.N : Jefferies raise
02-02 16:05
Regeneron’s Earnings Call: Growth Engines and Rising Costs
Regeneron Pharmaceuticals (($REGN)) has held its Q4 earnings call. Read on for ...
01-31 08:28
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks fell on Friday after President Donald Trump nominated for
01-31 02:38
Regeneron bets added cholesterol benefit will help its obesity drug stand out
Regeneron bets added cholesterol benefit will help its obesity drug stand out By Gnaneshwar Rajan and Sriparna Roy Jan 30 (Reuters) - Regeneron Pharmaceuticals' REGN.O executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give
01-31 01:38
Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory
Regeneron beat Q4 earnings and sales estimates as Dupixent gains offset weaker Eylea sales. The drugmaker also outlined 2026 margins, higher R&D spending, and a $2 billion U.S. factory plan.
01-30 23:56
Regeneron Pharmaceuticals shares are trading lower. The company reported Q4 financial results
Regeneron Pharmaceuticals shares are trading lower. The company reported Q4 fin...
01-30 21:45
Regeneron Pharmaceuticals Earnings Review: Q4 Summary
The earnings results for Regeneron Pharmaceuticals (NASDAQ:REGN) for Q4 were ma...
01-30 21:28
